Compare Stocks: ORMP, SLDB, DSGN, and ANNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.13 +3.0%	$4.81	$2.54 ▼ $7.18	$760.21M	1.21	3.02 million shs	3.51 million shs
DSGN Design Therapeutics	$12.62 +2.1%	$13.82	$5.28 ▼ $17.25	$773.51M	1.66	741,736 shs	655,798 shs
ORMP Oramed Pharmaceuticals	$4.69 -1.3%	$4.62	$2.09 ▼ $5.47	$197.59M	1.19	182,607 shs	170,664 shs
SLDB Solid Biosciences	$7.16 -1.6%	$8.86	$3.79 ▼ $11.45	$780.60M	2.44	1.21 million shs	1.39 million shs

10 Best Stocks to Own: Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+2.99%	-1.20%	-16.90%	-25.59%	+32.37%
DSGN Design Therapeutics	+2.10%	-4.10%	-16.48%	-13.92%	+84.23%
ORMP Oramed Pharmaceuticals	-1.26%	-1.26%	-6.76%	+1.74%	+73.70%
SLDB Solid Biosciences	-1.65%	-19.73%	-26.71%	-29.80%	+19.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.13 +3.0%	$4.81	$2.54 ▼ $7.18	$760.21M	1.21	3.02 million shs	3.51 million shs
DSGN Design Therapeutics	$12.62 +2.1%	$13.82	$5.28 ▼ $17.25	$773.51M	1.66	741,736 shs	655,798 shs
ORMP Oramed Pharmaceuticals	$4.69 -1.3%	$4.62	$2.09 ▼ $5.47	$197.59M	1.19	182,607 shs	170,664 shs
SLDB Solid Biosciences	$7.16 -1.6%	$8.86	$3.79 ▼ $11.45	$780.60M	2.44	1.21 million shs	1.39 million shs

10 Best Stocks to Own: Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+2.99%	-1.20%	-16.90%	-25.59%	+32.37%
DSGN Design Therapeutics	+2.10%	-4.10%	-16.48%	-13.92%	+84.23%
ORMP Oramed Pharmaceuticals	-1.26%	-1.26%	-6.76%	+1.74%	+73.70%
SLDB Solid Biosciences	-1.65%	-19.73%	-26.71%	-29.80%	+19.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	266.66% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	30.74% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
SLDB Solid Biosciences	2.85	Moderate Buy	$18.69	161.07% Upside

Current Analyst Ratings Breakdown

Latest ORMP, SLDB, DSGN, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/14/2026	SLDB Solid Biosciences	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/14/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform
7/21/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform	$3.00

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	$0.09 per share	52.36	$5.02 per share	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.14	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest ORMP, SLDB, DSGN, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.33%	N/A	6.07%	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DSGN Design Therapeutics	N/A	18.86	18.86
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DSGN Design Therapeutics	56.64%
ORMP Oramed Pharmaceuticals	12.73%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DSGN Design Therapeutics	17.10%
ORMP Oramed Pharmaceuticals	20.77%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable
SLDB Solid Biosciences	121	107.23 million	104.37 million	Optionable

ORMP, SLDB, DSGN, and ANNX Headlines

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 4.7% - Here's Why

September 29 at 12:59 PM | marketbeat.com

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

September 25, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Trading Down 10% - Time to Sell?

September 23, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns Outperform Rating from Analysts at Royal Bank Of Canada

September 19, 2026 | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) Upgraded to Moderate Buy at Royal Bank Of Canada

September 17, 2026 | marketbeat.com

RBC Capital initiates coverage of Solid Biosciences at outperform

September 17, 2026 | msn.com

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

September 16, 2026 | finance.yahoo.com

Solid Biosciences wins new Outperform at RBC on DMD opportunity

September 16, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Shares Down 6.4% - Time to Sell?

September 15, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright

September 14, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Analysts

September 14, 2026 | marketbeat.com

Solid Biosciences (SLDB) Gets a Buy from Citi

September 12, 2026 | theglobeandmail.com

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

243,154 Shares in Solid Biosciences Inc. $SLDB Purchased by Bank of New York Mellon Corp

September 8, 2026 | marketbeat.com

Solid Biosciences to Participate at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, SLDB, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$4.13 +0.12 (+2.99%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.09 (+2.28%)

As of 04:01 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Design Therapeutics NASDAQ:DSGN

$12.62 +0.26 (+2.10%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$12.65 +0.03 (+0.23%)

As of 04:20 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.69 -0.06 (-1.26%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$4.69 0.00 (0.00%)

As of 09/29/2026 07:30 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Solid Biosciences NASDAQ:SLDB

$7.16 -0.12 (-1.65%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$7.28 +0.12 (+1.73%)

As of 09/29/2026 07:53 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, SLDB, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, SLDB, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, SLDB, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, SLDB, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Oramed Pharmaceuticals NASDAQ:ORMP

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, SLDB, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, SLDB, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, SLDB, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, SLDB, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Oramed Pharmaceuticals NASDAQ:ORMP

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools